Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?

Group 1: Company Performance - Alkermes (ALKS) has shown a year-to-date performance increase of approximately 8%, outperforming the average return of 1.3% for Medical companies [4] - The Zacks Consensus Estimate for ALKS' full-year earnings has risen by 14.7% over the past 90 days, indicating a positive trend in analyst sentiment [3] - Alkermes holds a Zacks Rank of 1 (Strong Buy), suggesting strong potential for future performance [3] Group 2: Industry Context - Alkermes is part of the Medical - Biomedical and Genetics industry, which consists of 469 stocks and currently ranks 99 in the Zacks Industry Rank [5] - The Medical - Biomedical and Genetics industry has experienced an average gain of 11.4% this year, indicating that Alkermes is slightly underperforming its industry [5] - In contrast, Cardinal Health, which belongs to the Medical - Dental Supplies industry, has returned 66.4% year-to-date and has a Zacks Rank of 2 (Buy) [4][5]